XML 40 R37.htm IDEA: XBRL DOCUMENT
v2.4.1.9

Collaboration with Intrexon and OvaXon Joint Venture (Details) (USD $) | 12 Months Ended | 1 Months Ended
--- | --- | ---
Dec. 31, 2014 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2014
Collaboration with Intrexon |  |  |  |
Amount of newly issued common stock upon execution of collaborative arrangements |  | $ 2,500,000 ovas_StockIssuedValueUnderCollaborativeArrangement |  |
Technology access fee payable in cash upon specified passage of time | 2,500,000 ovas_CollaborativeArrangementsTechnologyAccessFeePayableInCashUponSpecifiedPassageOfTime |  |  | 2,500,000 ovas_CollaborativeArrangementsTechnologyAccessFeePayableInCashUponSpecifiedPassageOfTime
Research and development expense | 21,784,000 us-gaap_ResearchAndDevelopmentExpense | 15,802,000 us-gaap_ResearchAndDevelopmentExpense | 6,323,000 us-gaap_ResearchAndDevelopmentExpense |
OvaTure Collaboration |  |  |  |
Collaboration with Intrexon |  |  |  |
Period of commercial milestone payment after the first commercial sale of collaborative arrangement | 3 months |  |  |
Notice period for termination of the agreement by the counterparty | 90 days |  |  |
Minimum period available to counterparty to cure material breach done by other party to avoid termination of agreement | 60 days |  |  |
OvaTure Collaboration | Intrexon |  |  |  |
Collaboration with Intrexon |  |  |  |
Issuance of common stock shares upon execution of collaborative arrangements (in shares) |  | 273,224 ovas_StockIssuedSharesUnderCollaborativeArrangement / us-gaap_CounterpartyNameAxis = ovas_IntrexonIncMember / us-gaap_TypeOfArrangementAxis = us-gaap_CollaborativeArrangementMember |  |
Amount of newly issued common stock upon execution of collaborative arrangements |  | 2,500,000 ovas_StockIssuedValueUnderCollaborativeArrangement / us-gaap_CounterpartyNameAxis = ovas_IntrexonIncMember / us-gaap_TypeOfArrangementAxis = us-gaap_CollaborativeArrangementMember |  |
Technology access fee payable in cash upon specified passage of time | 2,500,000 ovas_CollaborativeArrangementsTechnologyAccessFeePayableInCashUponSpecifiedPassageOfTime / us-gaap_CounterpartyNameAxis = ovas_IntrexonIncMember / us-gaap_TypeOfArrangementAxis = us-gaap_CollaborativeArrangementMember |  |  | 2,500,000 ovas_CollaborativeArrangementsTechnologyAccessFeePayableInCashUponSpecifiedPassageOfTime / us-gaap_CounterpartyNameAxis = ovas_IntrexonIncMember / us-gaap_TypeOfArrangementAxis = us-gaap_CollaborativeArrangementMember
Research and development expense |  | 4,700,000 us-gaap_ResearchAndDevelopmentExpense / us-gaap_CounterpartyNameAxis = ovas_IntrexonIncMember / us-gaap_TypeOfArrangementAxis = us-gaap_CollaborativeArrangementMember |  |
Research and development expense recorded to additional paid-in capital and common stock | 2,500,000 ovas_CollaborativeArrangementsResearchAndDevelopmentExpenseRecordedInAdditionalPaidInCapitalAndCommonStock / us-gaap_CounterpartyNameAxis = ovas_IntrexonIncMember / us-gaap_TypeOfArrangementAxis = us-gaap_CollaborativeArrangementMember |  |  |
Research and development expense recorded in accrued liabilities |  | 2,200,000 ovas_CollaborativeArrangementsResearchAndDevelopmentExpenseRecordedInAccruedLiabilities / us-gaap_CounterpartyNameAxis = ovas_IntrexonIncMember / us-gaap_TypeOfArrangementAxis = us-gaap_CollaborativeArrangementMember |  |
Period of royalty payable depending upon completion of milestone within targeted deadline after transfer of technology | 2 years |  |  |
Maximum | OvaTure Collaboration | Intrexon |  |  |  |
Collaboration with Intrexon |  |  |  |
Research and development, accreted liability |  |  |  | $ 2,500,000 us-gaap_AccretionExpense / us-gaap_CounterpartyNameAxis = ovas_IntrexonIncMember / us-gaap_RangeAxis = us-gaap_MaximumMember / us-gaap_TypeOfArrangementAxis = us-gaap_CollaborativeArrangementMember

X
- Definition Represents the minimum period available to counterparty to cure material breach done by other party to avoid termination of agreement. + References No definition available. + Details
Name: | ovas_CollaborativeArrangementsMinimumPeriodAvailableToCounterpartyToCureMaterialBreachDoneByOtherPartyToAvoidTerminationOfAgreementByEntity
Namespace Prefix: | ovas_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the notice period for termination of the agreement by the counterparty. + References No definition available. + Details
Name: | ovas_CollaborativeArrangementsNoticePeriodForTerminationOfAgreementByCounterparty
Namespace Prefix: | ovas_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the period of royalty payable depending upon completion of milestone within targeted deadline after transfer of technology. + References No definition available. + Details
Name: | ovas_CollaborativeArrangementsPeriodOfRoyaltyPayableDependingUponCompletionOfMilestoneWithinTargetedDeadlineAfterTransferOfTechnology
Namespace Prefix: | ovas_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the amount of research and development expense recorded in accrued liabilities under collaborative arrangements. + References No definition available. + Details
Name: | ovas_CollaborativeArrangementsResearchAndDevelopmentExpenseRecordedInAccruedLiabilities
Namespace Prefix: | ovas_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Represents the amount of research and development expense recorded to additional paid-in capital and common stock under collaborative arrangements. + References No definition available. + Details
Name: | ovas_CollaborativeArrangementsResearchAndDevelopmentExpenseRecordedInAdditionalPaidInCapitalAndCommonStock
Namespace Prefix: | ovas_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Represents the amount of technology access fee payable in cash upon specified passage of time under collaborative arrangement. + References No definition available. + Details
Name: | ovas_CollaborativeArrangementsTechnologyAccessFeePayableInCashUponSpecifiedPassageOfTime
Namespace Prefix: | ovas_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Represents the period of commercial milestone payment after the first commercial sale of collaborative arrangement. + References No definition available. + Details
Name: | ovas_PeriodOfCommercialMilestonePaymentAfterFirstCommercialSaleOfCollaborativeArrangement
Namespace Prefix: | ovas_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Equity impact of the shares of stock issued during the period under collaborative arrangement. + References No definition available. + Details
Name: | ovas_StockIssuedSharesUnderCollaborativeArrangement
Namespace Prefix: | ovas_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Equity impact of the value of stock issued during the period under collaborative arrangement. + References No definition available. + Details
Name: | ovas_StockIssuedValueUnderCollaborativeArrangement
Namespace Prefix: | ovas_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount recognized for the passage of time, typically for liabilities, that have been discounted to their net present values. Excludes accretion associated with asset retirement obligations. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 410 -SubTopic 20 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6392676&loc=d3e7480-110848 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section 35 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=6394232&loc=d3e17558-110866 + Details
Name: | us-gaap_AccretionExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_RangeAxis=us-gaap_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |